Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Overview
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Companies Involved in Therapeutics Development
AngioChem Inc
AVROBIO Inc
Bioasis Technologies Inc
Deli Therapeutics Inc
Esteve Pharmaceuticals SA
GC Pharma
Generium
Homology Medicines Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
ReqMed Co Ltd
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Drug Profiles
AVRRD-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Idurote 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNR-055 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMI-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pabifusp alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Idurote 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIG-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xB-3008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Product Development Milestones
Featured News & Press Releases
Nov 03, 2021: AVROBIO receives Rare Pediatric Disease Desigtion from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
Nov 02, 2021: GC Green Cross desigted as a European orphan drug for the treatment of severe Hunter syndrome
Oct 20, 2021: Homology Medicines announces presentation of data supporting clinical programs in MPS II and PKU, including nonclinical and patient-focused research, at American Society of Human Genetics Meeting
Oct 18, 2021: Homology medicines initiates clinical trial for HMI-203, a one-time investigatiol gene therapy candidate for adults with MPS II (Hunter Syndrome)
Oct 18, 2021: JCR Pharmaceuticals Co : EMA grants PRIME desigtion for JR-141 for the treatment of Mucopolysaccharidosis type II (Hunter Syndrome)
Oct 15, 2021: JR-141 (Pabifusp Alfa) for Hunter syndrome notice on the publication of a nonclinical and clinical evidence in Intertiol Jourl of Molecular Sciences
Jul 29, 2021: JCR Pharmaceuticals announces presentation at 16th Intertiol Symposium on MPS and Related Diseases.
Jul 29, 2021: JR-141 (Pabifusp Alfa) for Hunter Syndrome notice on the publication of a case report in Japan in JIMD reports
May 19, 2021: JCR Pharmaceuticals: Launch of IZCARGO I.V. infusion 10mg (JR-141: Pabifusp Alfa) for treatment of MPS II (Hunter Syndrome) in Japan
Apr 19, 2021: JR-141 (Pabifusp Alfa) for Hunter Syndrome notice on the publication of the results of non-clinical trials in molecular genetics and metabolism report
Mar 23, 2021: JCR Pharmaceuticals announces approval of IZCARGO (pabifusp alfa) for treatment of MPS II (Hunter syndrome) in Japan
Mar 03, 2021: GC Green Cross to ship’Hunterase ICV’ in Japan
Feb 10, 2021: JCR Pharmaceuticals receives FDA IND clearance to initiate global phase 3 clinical trial of JR-141 for Mucopolysaccharidosis Type II (Hunter Syndrome)
Feb 10, 2021: FDA grants fast track desigtion for JR-141 for the treatment of mucopolysaccharidosis type II (Hunter syndrome)
Feb 08, 2021: Homology Medicines announces first presentation of data with HMI-203 in vivo gene therapy development candidate for Hunter syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by AngioChem Inc, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by AVROBIO Inc, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Bioasis Technologies Inc, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Denali Therapeutics Inc, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Esteve Pharmaceuticals SA, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by GC Pharma, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Generium, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Homology Medicines Inc, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Immusoft Corp, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by JCR Pharmaceuticals Co Ltd, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by RegenxBio Inc, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by ReqMed Co Ltd, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Sigilon Therapeutics Inc, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects, 2021
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products, 2021